Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma

Roman Hájek; Ji Minarík; Jan Straub; Lud k. Pour; Alexandra Jungova; Jesus G. Berdeja; Mario Boccadoro; Lucie Brozova; Andrew Spencer; Frits Van Rhee; Jorge Vela-Ojeda; Michael A. Thompson; Rafat Abonour; Ajai Chari; Gordon Cook; Caitlin L. Costello; Faith E. Davies; Vania T.M. Hungria; Hans C. Lee; Xavier Leleu; Noemi Puig; Robert M. Rifkin; Evangelos Terpos; Saad Z. Usmani; Katja C. Weisel; Jeffrey A. Zonder; Magda Barinová; Matyáš Kuhn; Ji Šilar; Lenka Cápková; Kenny Galvez; Jin Lu; Jennifer Elliott; Dawn Marie Stull; Kaili Ren; Vladimír Maisnar

doi:10.2217/fon-2020-1225

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma

Roman Hájek, Ji Minarík, Jan Straub, Lud k. Pour, Alexandra Jungova, Jesus G. Berdeja, Mario Boccadoro, Lucie Brozova, Andrew Spencer, Frits Van Rhee, Jorge Vela-Ojeda, Michael A. Thompson, Rafat Abonour, Ajai Chari, Gordon Cook, Caitlin L. Costello, Faith E. Davies, Vania T.M. Hungria, Hans C. Lee, Xavier LeleuNoemi Puig, Robert M. Rifkin, Evangelos Terpos, Saad Z. Usmani, Katja C. Weisel, Jeffrey A. Zonder, Magda Barinová, Matyáš Kuhn, Ji Šilar, Lenka Cápková, Kenny Galvez, Jin Lu, Jennifer Elliott, Dawn Marie Stull, Kaili Ren, Vladimír Maisnar

Lymphoma-Myeloma

Research output: Contribution to journal › Article › peer-review

12 Scopus citations

Abstract

Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)</ext-link.

Original language	English (US)
Pages (from-to)	2499-2512
Number of pages	14
Journal	Future Oncology
Volume	17
Issue number	19
DOIs	https://doi.org/10.2217/fon-2020-1225
State	Published - Jul 2021

Keywords

effectiveness
ixazomib
multiple myeloma
proteasome inhibitor
relapsed/refractory
routine clinical practice

ASJC Scopus subject areas

Oncology
Cancer Research

Access to Document

10.2217/fon-2020-1225

Cite this

Hájek, R., Minarík, J., Straub, J., Pour, L. K., Jungova, A., Berdeja, J. G., Boccadoro, M., Brozova, L., Spencer, A., Van Rhee, F., Vela-Ojeda, J., Thompson, M. A., Abonour, R., Chari, A., Cook, G., Costello, C. L., Davies, F. E., Hungria, V. T. M., Lee, H. C., ... Maisnar, V. (2021). Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma. Future Oncology, 17(19), 2499-2512. https://doi.org/10.2217/fon-2020-1225

Hájek, R, Minarík, J, Straub, J, Pour, LK, Jungova, A, Berdeja, JG, Boccadoro, M, Brozova, L, Spencer, A, Van Rhee, F, Vela-Ojeda, J, Thompson, MA, Abonour, R, Chari, A, Cook, G, Costello, CL, Davies, FE, Hungria, VTM, Lee, HC, Leleu, X, Puig, N, Rifkin, RM, Terpos, E, Usmani, SZ, Weisel, KC, Zonder, JA, Barinová, M, Kuhn, M, Šilar, J, Cápková, L, Galvez, K, Lu, J, Elliott, J, Stull, DM, Ren, K & Maisnar, V 2021, 'Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma', Future Oncology, vol. 17, no. 19, pp. 2499-2512. https://doi.org/10.2217/fon-2020-1225

@article{8af7056d322d42b9ac8ae814c667391a,

title = "Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma",

abstract = "Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)",

keywords = "effectiveness, ixazomib, multiple myeloma, proteasome inhibitor, relapsed/refractory, routine clinical practice",

author = "Roman H{\'a}jek and Ji Minar{\'i}k and Jan Straub and Pour, {Lud k.} and Alexandra Jungova and Berdeja, {Jesus G.} and Mario Boccadoro and Lucie Brozova and Andrew Spencer and {Van Rhee}, Frits and Jorge Vela-Ojeda and Thompson, {Michael A.} and Rafat Abonour and Ajai Chari and Gordon Cook and Costello, {Caitlin L.} and Davies, {Faith E.} and Hungria, {Vania T.M.} and Lee, {Hans C.} and Xavier Leleu and Noemi Puig and Rifkin, {Robert M.} and Evangelos Terpos and Usmani, {Saad Z.} and Weisel, {Katja C.} and Zonder, {Jeffrey A.} and Magda Barinov{\'a} and Maty{\'a}{\v s} Kuhn and Ji {\v S}ilar and Lenka C{\'a}pkov{\'a} and Kenny Galvez and Jin Lu and Jennifer Elliott and Stull, {Dawn Marie} and Kaili Ren and Vladim{\'i}r Maisnar",

year = "2021",

month = jul,

doi = "10.2217/fon-2020-1225",

language = "English (US)",

volume = "17",

pages = "2499--2512",

journal = "Future Oncology",

issn = "1479-6694",

publisher = "Future Medicine Ltd.",

number = "19",

}

TY - JOUR

T1 - Ixazomib-lenalidomide-dexamethasone in routine clinical practice

T2 - Effectiveness in relapsed/refractory multiple myeloma

AU - Hájek, Roman

AU - Minarík, Ji

AU - Straub, Jan

AU - Pour, Lud k.

AU - Jungova, Alexandra

AU - Berdeja, Jesus G.

AU - Boccadoro, Mario

AU - Brozova, Lucie

AU - Spencer, Andrew

AU - Van Rhee, Frits

AU - Vela-Ojeda, Jorge

AU - Thompson, Michael A.

AU - Abonour, Rafat

AU - Chari, Ajai

AU - Cook, Gordon

AU - Costello, Caitlin L.

AU - Davies, Faith E.

AU - Hungria, Vania T.M.

AU - Lee, Hans C.

AU - Leleu, Xavier

AU - Puig, Noemi

AU - Rifkin, Robert M.

AU - Terpos, Evangelos

AU - Usmani, Saad Z.

AU - Weisel, Katja C.

AU - Zonder, Jeffrey A.

AU - Barinová, Magda

AU - Kuhn, Matyáš

AU - Šilar, Ji

AU - Cápková, Lenka

AU - Galvez, Kenny

AU - Lu, Jin

AU - Elliott, Jennifer

AU - Stull, Dawn Marie

AU - Ren, Kaili

AU - Maisnar, Vladimír

PY - 2021/7

Y1 - 2021/7

N2 - Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)

AB - Aim: To evaluate the effectiveness and safety of ixazomib-lenalidomide-dexamethasone (IRd) in relapsed/refractory multiple myeloma in routine clinical practice. Patients & methods: Patient-level data from the global, observational INSIGHT MM and the Czech Registry of Monoclonal Gammopathies were integrated and analyzed. Results: At data cut-off, 263 patients from 13 countries were included. Median time from diagnosis to start of IRd was 35.8 months; median duration of follow-up was 14.8 months. Overall response rate was 73%, median progression-free survival, 21.2 months and time-to-next therapy, 33.0 months. Ixazomib/lenalidomide dose reductions were required in 17%/36% of patients; 32%/30% of patients discontinued ixazomib/lenalidomide due to adverse events. Conclusion: The effectiveness and safety of IRd in routine clinical practice are comparable to those reported in TOURMALINE-MM1. Clinical trial registration: NCT02761187 (ClinicalTrials.gov)

KW - effectiveness

KW - ixazomib

KW - multiple myeloma

KW - proteasome inhibitor

KW - relapsed/refractory

KW - routine clinical practice

UR - http://www.scopus.com/inward/record.url?scp=85108000931&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85108000931&partnerID=8YFLogxK

U2 - 10.2217/fon-2020-1225

DO - 10.2217/fon-2020-1225

M3 - Article

C2 - 33769076

AN - SCOPUS:85108000931

SN - 1479-6694

VL - 17

SP - 2499

EP - 2512

JO - Future Oncology

JF - Future Oncology

IS - 19

ER -

Ixazomib-lenalidomide-dexamethasone in routine clinical practice: Effectiveness in relapsed/refractory multiple myeloma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this